


# Cavilon™



# Proactive Protection



Skin damage from adhesives at infusion catheter sites can be a significant problem, particularly for those with fragile skin

## 3M™ Cavilon™ No Sting Barrier Film is the ideal solution to protect skin around the infusion catheter site

### Cavilon No Sting Barrier Film:

- Forms a breathable transparent protective coating between the skin and the adhesive of the securement dressing device or tape
- When the dressing is changed, Cavilon No Sting Barrier Film is removed instead of skin cell layers<sup>5</sup>

### Cavilon No Sting Barrier Film is like no other barrier film


**7 key characteristics** make it the intelligent choice to help prevent adhesive trauma around infusion catheter sites:

- **Contains a unique blend of not one, but two polymers**  
The additional polymer allows the film to flex with the skin and maintain a continuous protective coating.<sup>6</sup> Other barrier films contain only one polymer.
- **Chlorhexidine gluconate and povidone iodine compatible**<sup>7</sup>  
To ensure effectiveness of antimicrobial preps, only barrier films with proven compatibility should be used
- **Alcohol-free and non-stinging**—comfortable for use on damaged skin<sup>8</sup>
- **Non-cytotoxic**—will not interfere with healing if skin is damaged<sup>9</sup>
- **Fast-drying and non-sticky**—for ease of use and patient comfort<sup>10</sup>
- **Hypoallergenic**<sup>11</sup>
- **Unique delivery system**—Accepted standards of practice<sup>12</sup> call for sterile technique and supplies; easy to open peel down packaging allows for aseptic delivery



### Proven to protect skin from Medical Adhesive-Related Skin Injury (MARS) <sup>13,14,15,16</sup>

A recent study evaluated skin condition in patients with peripherally inserted central catheters (PICC). A significant decrease in local skin complications with use of Cavilon No Sting Barrier Film was demonstrated.<sup>13</sup>



- Frequent or repeated dressings changes can result in skin stripping injuries that compromise the epidermis or even more seriously, create a superficial wound<sup>1</sup>
- Skin damage is a local complication that can lead to increased risk of colonization and infection<sup>2,3</sup>
- Local complications and certainly catheter related blood stream infections (CRBSI) are undesirable and represent serious negative clinical outcomes
- Treatment costs for a CRBSI can cost between \$4,000 and \$56,000 per infection<sup>4</sup>


## Application Instructions

3M™ Cavilon™ No Sting Barrier Film 1 mL wand applicator is recommended for skin protection around intravenous catheter sites.

**NOTE!** The 28 mL spray bottle should not be used for IV site protection.

### Application at time of catheter insertion:

1. **Prepare for and follow catheter insertion** procedure per facility protocol.
2. **Apply antiseptic prep** and allow to dry completely. 🕒
3. **Insert catheter.**
4. **Apply barrier film:** Avoiding the area immediately surrounding insertion site (approximately 2cm), apply an even coating of Cavilon No Sting Barrier Film to the area that will be covered by the adhesive dressing/device. If using Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing do not apply the film to skin where the CHG gel pad is placed.
5. **Allow Cavilon No Sting Barrier Film to dry completely** (approximately 30 seconds). 🕒
6. **Apply dressing:** Tegaderm™ I.V. Advanced Securement Dressing or Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing or 3M™ PICC/CVC Securement System per protocol.



### Application at dressing change:

1. **Prepare for and follow dressing change procedure** per facility protocol.
2. **Remove securement dressing/device.**  
**NOTE!** Cavilon No Sting Barrier Film forms a protective interface between skin and the adhesive. It is removed with the adhesive product and must be reapplied with each dressing change.
3. **Apply antiseptic prep** and allow to dry completely. 🕒
4. **Apply barrier film:** Avoiding the area immediately surrounding insertion site (approximately 2cm), apply an even coating of Cavilon No Sting Barrier Film to the area that will be covered by the adhesive dressing/device. If using Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing do not apply the film to skin where the CHG gel pad is placed.
5. **Allow Cavilon No Sting Barrier Film to dry completely** (approximately 30 seconds). 🕒
6. **Apply dressing:** Tegaderm™ I.V. Advanced Securement Dressing or Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing or 3M™ PICC/CVC Securement System per protocol.



=  
allow dry time

# 3M™ Cavilon™ No Sting Barrier Film

Catalog No.	Product	Size	Items/Box	Boxes/Case	HCPCS Code
<b>3343</b>	<b>3M™ Cavilon™ No Sting Barrier Film</b>	<b>1 mL wand</b>	<b>25</b>	<b>4</b>	<b>A6250</b>
3344	3M™ Cavilon™ No Sting Barrier Film	1 mL wipe	25	4	A6250
3345	3M™ Cavilon™ No Sting Barrier Film	3 mL wand	25	4	A6250

**Disclaimer:**

HCPCS codes have been provided to assist you in the preparation of insurance claims. Please note, however, that the reimbursement information provided by 3M Health Care and its representatives is intended to provide general information relevant to coverage and coding for 3M products. Insurers' reimbursement policies can vary and the use of the codes discussed here does not guarantee that an insurer will cover or pay at any particular level. Health care providers should exercise independent clinical judgment in choosing the codes which most accurately describe the products provided.

## Evidence-based

There are over 70 pieces of clinical evidence<sup>17</sup> supporting the efficacy and cost-effectiveness of Cavilon No Sting Barrier Film for multiple clinical uses. This represents more evidence than any other moisture barrier or barrier film.



## References

- McNichol L, Lund C, Rosen T, Gray M. Medical Adhesives and Patient Safety: State of the Science: Consensus Statements for the Assessment, Prevention, and Treatment of Adhesive-Related Skin Injuries. *J Wound Ostomy Continence Nurs.* 2013;40(4): 365-380.
- Wysocki AB. Anatomy and Physiology of Skin and Soft Tissue. In: Bryant, RA and Nix DP eds. *Acute and Chronic Wounds: Current Management Concepts.* 4th ed. St Louis, MO: Elsevier Mosby; 2012: 40-62.
- Roth RR and James WD. Microbial Ecology of the Skin. *Annu. Rev. Microbiol.* 1988; 42: 441-464.
- Abad CL and Safdar N. Catheter-related Bloodstream Infections. *Infectious Disease.* (Special Edition) 2011. McMahon Publishing.
- 3M Data on file 2013; CLIN-MISC-US-05-202211.
- 3M Data on file 2012; CLIN-MISC-US-05-201292.
- 3M Data on file 2009; I2MS 11230.
- 3M Data on file 2004; I2MS 10029.
- 3M Data on file 2004; I2MS 10030.
- 3M Data on file 2011; CLIN-MISC-US-05-169008.
- 3M Data on file 2004; I2MS 10031.
- Gorski LA et al. Infusion Nursing Standards of Practice. *J of Infusion Nursing.* 2011; 34(1): S25.
- George M. Role of skin protectant in reducing the local complications in PICC lines. Poster presentation at the 2013 meeting of the Infusion Nursing Society.
- Link D and Cutler C. In search of a better central line dressing in the autologous bone marrow reinfusion patient. 1998. 3M White Paper.
- Campbell K et al. A Clinical Evaluation of 3M™ Cavilon™ No Sting Barrier Film. *Ostomy Wound Management.* 2000; 46(1):24-30.
- Grove GL et al. Comparison of the skin protection properties of various film forming skin protectants. Poster presentation at the Wound, Ostomy, and Continence Nurses Society Annual Conference. 1993.
- 3M Health Care. Cavilon No Sting Barrier Film. Clinical Evidence Summaries. 2012.



**Critical & Chronic Care Solutions Division**  
**3M Health Care**  
 2510 Conway Avenue  
 St. Paul, MN 55144  
 USA  
 1-800-228-3957  
[www.3M.com/Cavilon](http://www.3M.com/Cavilon)

3M, Cavilon and Tegaderm are trademarks of 3M. Used under license in Canada. Please recycle. Printed in USA.

© 3M 2014. All rights reserved.  
 70-2011-5544-0

# Simplifying your skin integrity needs.



## 3M™ Cavilon™ Advanced Skin Protectant

3M™ Cavilon™ Advanced Skin Protectant is a highly durable, ultra-thin, transparent barrier which protects against the harmful effects of bodily fluids. This barrier creates a protective environment that supports healing and reduces pain associated with skin breakdown due to urine and/or faeces.<sup>14</sup>

- ▶ Application only needed twice per week<sup>14</sup>
- ▶ Attaches to wet, weepy, damaged skin<sup>14</sup>
- ▶ Single-use applicator reduces the potential for cross-contamination
- ▶ Reduces the pain of managing IAD<sup>14</sup>
- ▶ Breathable, allowing for moisture-vapour transmission that helps keep skin comfortable
- ▶ Creates an environment that supports healing<sup>15</sup>



## 3M™ Cavilon™ No Sting Barrier Film

Cavilon No Sting Barrier Film is a durable terpolymer-based alcohol-free barrier film, which forms a breathable, transparent protective coating on the skin to protect from friction, adhesive trauma and bodily fluids (such as urine and/or faeces and wound exudate).

- ▶ Does not sting, even on broken or irritated skin<sup>16</sup>
- ▶ Does not clog the linings of protective incontinence pads<sup>17</sup>
- ▶ Cost effective – provides up to 72 hours protection<sup>18</sup>
- ▶ Transparent – for easy monitoring of skin
- ▶ Compatible with skin prep solutions (i.e. chlorhexidine gluconate and povidone iodone)<sup>19</sup>
- ▶ Allows adhesion of tapes, dressings and devices<sup>19</sup>
- ▶ Allows moisture vapor transmission from the skin
- ▶ No need to remove between applications

#### References

- 1 Gray M, Bartos S. Incontinence Associated Dermatitis in the Acute Care Setting: A Prospective Multi-site Epidemiologic Study. Presented at the 23rd Annual Meeting of the Wound Healing Society. 2013.
- 2 Excellence in Continence Care: Practical guidance for commissioners and leaders in health and social care, NHS England, June 2018.
- 3 Colwell JC, McNichol L, Boarini J. North America Wound, Ostomy, and Continence and Enterostomal Therapy Nurses Current Ostomy Care Practice Related to Peristomal Skin Issues *J Wound Ostomy Continence Nurs.* 2017; 44(3): 257–261.
- 4 Pressure ulcers: revised definition and measurement. Summary and recommendations, NHSI, June 2018.
- 5 Beeckman D. *et al.* A systematic review and meta-analysis of incontinence-associated dermatitis. Incontinence and moisture as risk factors for pressure ulcer development. *Research in Nursing & Health.* 2014.
- 6 National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline. Emily Haesler (Ed.). Cambridge Media: Osborne Park, Western Australia; 2014.
- 7 VanGuilder, C., MacFarlane, G. D., & Meyer, S. (2008). Results of Nine International Pressure Ulcer Prevalence Surveys: 1989 to 2005. *Ostomy Wound Management*, 54(2).
- 8 Demarre L *et al.* Factors predicting the development of pressure ulcers in an at-risk population who receive standardized preventive care: secondary analyses of a multicentre randomised controlled trial. *J Adv Nurs.* 2015;71(2):391–403.
- 9 Cutting KF. Impact of adhesive surgical tape and wound dressing on the skin with reference to skin stripping. *J Wound Care* 2008;157-158,160–162.
- 10 Zhao H, *et al.* Prevalence of medical adhesive-related skin injury at peripherally inserted central catheter insertion site in oncology patients. *J Vasc Access.* 2017 Nov 8;0. doi: 10.5301/jva.5000805.
- 11 Maene, B. Hidden costs of medical tape-induced skin injuries. *Wounds UK.* 2013; 9(1), 46–50.
- 12 Campbell J, Coyer F, Osborne S. The Skin Safety Model: Reconceptualizing Skin Vulnerability in Older Patients. *J. of Nurs Scholarship.* 2016; 48(1):14–22.
- 13 McNichol L, Lund C, Rosen T, Gray M: Medical adhesives and patient safety: state of the science: consensus statements for the assessment, prevention, and treatment of adhesive-related skin injuries. *Orthop Nurs.* 2013 Sep-Oct;32(5):267–81.
- 14 Brennan, Mary R.; Milne, Catherine T.; Agrell-Kann, Marie; Ekholm, Bruce P. Clinical Evaluation of a Skin Protectant for the Management of Incontinence Associated Dermatitis: An Open-Label, Nonrandomized, Prospective Study. *J of Wound, Ostomy & Continence Nursing.* 2017. 44(2):172–180.
- 15 3M data on file. EM-05-01 3924.
- 16 Arrowsmith, M, Schuren J, (2005) Laboratory Studies and general characteristics of Cavilon skin care products, 3M data on file.
- 17 Zehrer C, Newman D, Grove G. (2005) Assessment of Diaper - Clogging Potential of Petrolatum Moisture Barriers. *Ostomy Wound Management* 51 (12) 54–58.
- 18 Issberner K, Schuren J, A Comparative study of the Skin Protectant performance of five Barrier Films. 3M Germany Laboratory, Neuss, Germany, 2004.
- 19 3M Data on file.
- 20 Bale S, Tebble N, Jones V, Price P. (2004) The benefits of implementing a new skin care protocol in nursing homes. *Journal of Tissue Viability* 2004; 14(2)44–50.
- 21 Hart J. (2002) Assessment of the incontinence pad blocking potential of Cavilon DBC compared with Sudocrem and Zinc and Castor oil. *Nursing Scotland* 2002, Issue July/August.
- 22 Beeckman D *et al.* Proceedings of the Global IAD Expert Panel. Incontinence associated dermatitis: moving prevention forward. *Wounds International* 2015.

**3M United Kingdom PLC**  
Charnwood Campus  
10 Bakewell Road  
Loughborough  
LE11 5RB  
+44 (0)1509 611 611

**3M Ireland Limited**  
The Iveagh Building  
The Park, Carrickmines  
D18 X015  
Ireland  
+353 (0)1 280 3555

J458053.

3M and Cavilon are trademarks of 3M Company.  
© 3M 2019. All rights reserved.





***Declaration of Conformity***

As Legal Manufacturer  
We, 3M Company,  
2510 Conway Ave  
St Paul, Minnesota 55144  
USA

hereby declare under our sole responsibility  
that the CE marked products to which this declaration relates,

3M™ Cavilon™ No Sting Barrier Film  
Product numbers:  
3343E (1 ml swab), 3343E/10 (1 ml swab), 3343P (1 ml swab)  
3344E (1 ml wipe)  
3345E (3 ml swab), 3345P (3 ml swab)  
For Nordic market: 3343N (1 ml swab), 3345N (3 ml swab)

are classified,  
per Rule 4 of Annex IX of the Medical Device Directive 93/42/EEC, as amended per 2007/47/EC  
as a Class Is device  
and

is in accordance with Annex(es) V (sterilization) and VII of Directive 93/42/EEC, as amended per 2007/47/EC,  
on the approximation of the laws of the European Union Member States concerning medical devices.

This declaration is made on the basis of the quality assurance certificate CE 00493 delivered by BSI, 2797

EU Representative Address  
3M Deutschland GmbH  
Health Care Business  
Carl-Schurz-Str. 1  
41453 Neuss, Germany

Signature:



3M Health Care  
Division Regulatory Affairs Manager  
Medical Solutions Division